研究者情報

キクチ　エイジ   KIKUCHI EIJI   菊地栄次    所属   医学部医学科 腎泌尿器外科学    職種   主任教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
掲載誌名	正式名：International journal of clinical oncology 略　 称：Int J Clin Oncol ISSNコード：1437777213419625
掲載区分	国外
巻・号・頁	24(5),546-553頁
著者・共著者	Shigeta Keisuke, Kosaka Takeo, Hongo Hiroshi, Yanai Yoshinori, Matsumoto Kazuhiro, Morita Shinya, Mizuno Ryuichi, Shinojima Toshiaki, Kikuchi Eiji, Oya Mototsugu
発行年月	2019/05
概要	BACKGROUND:Our specific aim was to investigate the prognostic value of effective duration of first androgen deprivation therapy (ADT) and to evaluate the clinical impact on early docetaxel administration with oncological outcomes in castration-resistant prostate cancer (CRPC) patients treated with docetaxel.METHODS:We identified 148 mCRPC patients who were treated with 75 mg/m2RESULTS:Overall, 81 (54.7%) patients died. The median 1st ADT response was 22.2 months and the median time interval from CRPC onset to docetaxel treatment was 11.7 months. Multivariate analysis indicated that visceral metastasis, bone metastasis extent of disease (EOD) ≥ 2, and effective duration of ADT < 16 months were the independent prognostic indicators for progression-free survival (PFS). Referring to cancer-specific survival (CSS), besides visceral metastasis and effective duration of ADT < 16 months, late docetaxel treatment ≥ 12 months became as the predictors for poor prognosis. Among the ADT poor-responder group (ADT < 16 months), Kaplan-Meier method showed that 1-year and 2-year CSS rates were 96.0% and 80.0% in the patients who introduced docetaxel in early setting (< 12 months), which were significantly higher than those who introduced in late settings (93.6% and 30.8%, respectively, p < 0.001).CONCLUSION:CRPC patients who had poor response during 1st ADT would obtain survival benefit by introducing docetaxel treatment in early stage.
DOI	10.1007/s10147-018-01388-5
PMID	30604159